全文获取类型
收费全文 | 263238篇 |
免费 | 71683篇 |
国内免费 | 3993篇 |
专业分类
耳鼻咽喉 | 6424篇 |
儿科学 | 9451篇 |
妇产科学 | 3577篇 |
基础医学 | 25709篇 |
口腔科学 | 7443篇 |
临床医学 | 41852篇 |
内科学 | 74643篇 |
皮肤病学 | 15313篇 |
神经病学 | 28533篇 |
特种医学 | 10770篇 |
外国民族医学 | 8篇 |
外科学 | 58217篇 |
综合类 | 3536篇 |
现状与发展 | 74篇 |
一般理论 | 33篇 |
预防医学 | 13248篇 |
眼科学 | 5519篇 |
药学 | 11519篇 |
19篇 | |
中国医学 | 2524篇 |
肿瘤学 | 20502篇 |
出版年
2024年 | 570篇 |
2023年 | 5190篇 |
2022年 | 2412篇 |
2021年 | 6556篇 |
2020年 | 12140篇 |
2019年 | 14062篇 |
2018年 | 16998篇 |
2017年 | 18091篇 |
2016年 | 19860篇 |
2015年 | 20493篇 |
2014年 | 27809篇 |
2013年 | 28698篇 |
2012年 | 13077篇 |
2011年 | 13071篇 |
2010年 | 20325篇 |
2009年 | 20445篇 |
2008年 | 10297篇 |
2007年 | 7464篇 |
2006年 | 9824篇 |
2005年 | 6693篇 |
2004年 | 5523篇 |
2003年 | 4385篇 |
2002年 | 4293篇 |
2001年 | 5910篇 |
2000年 | 4846篇 |
1999年 | 4419篇 |
1998年 | 4161篇 |
1997年 | 3892篇 |
1996年 | 3702篇 |
1995年 | 3504篇 |
1994年 | 2188篇 |
1993年 | 1759篇 |
1992年 | 1649篇 |
1991年 | 1669篇 |
1990年 | 1323篇 |
1989年 | 1389篇 |
1988年 | 1206篇 |
1987年 | 1028篇 |
1986年 | 1028篇 |
1985年 | 825篇 |
1984年 | 615篇 |
1983年 | 575篇 |
1982年 | 550篇 |
1981年 | 453篇 |
1980年 | 384篇 |
1979年 | 351篇 |
1978年 | 361篇 |
1977年 | 429篇 |
1975年 | 301篇 |
1972年 | 329篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
1.
2.
3.
4.
5.
6.
7.
8.
Zeyu Li Erwei Hao Rui Cao Si Lin Linghui Zou Tianyan Huang Zhengcai Du Xiaotao Hou Jiagang Deng 《中草药(英文版)》2022,14(4):479-493
Zedoary tumeric (Curcumae Rhizoma, Ezhu in Chinese) has a long history of application and has great potential in the treatment of liver cancer. The anti liver cancer effect of zedoary tumeric depends on the combined action of multiple pharmacodynamic substances. In order to clarify the specific mechanism of zedoary tumeric against liver cancer, this paper first analyzes the mechanism of its single pharmacodynamic substance against liver cancer, and then verifies the joint anti liver cancer mechanism of its "pharmacodynamic group". By searching the research on the anti hepatoma effect of active components of zedoary tumeric in recent years, we found that pharmacodynamic substances, including curcumol, zedoarondiol, curcumenol, curzerenone, curdione, curcumin, germacrone, β-elemene, can act on multi-target and multi-channel to play an anti hepatoma role. For example, curcumin can regulate miR, GLO1, CD133, VEGF, YAP, LIN28B, GPR81, HCAR-1, P53 and PI3K/Akt/mTOR, HSP70/TLR4 and NF-κB. Wnt/TGF/EMT, Nrf2/Keap1, JAK/STAT and other pathways play an anti hepatoma role. Network pharmacological analysis showed that the core targets of the "pharmacodynamic group" for anti-life cancer are AKT1, EGFR, MAPK8, etc, and the core pathways are neuroactive live receiver interaction, nitrogen metabolism, HIF-1 signaling pathway, etc. At the same time, by comparing and analyzing the relationship between the specific mechanisms of pharmacodynamic substance and "pharmacodynamic group", it is found that they have great reference significance in target, pathway, biological function, determination of core pharmacodynamic components, formation of core target protein interaction, in-depth research of single pharmacodynamic substance, increasing curative effect and so on. By analyzing the internal mechanism of zedoary tumeric pharmacodynamic substance and "pharmacodynamic group" in the treatment of liver cancer, this paper intends to provide some ideas and references for the deeper pharmacological research of zedoary tumeric and the relationship between pharmacodynamic substance and "pharmacodynamic group". 相似文献
9.
10.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献